“The phase-3 trial has not ended yet,” said the official, adding that the company needs to carry out follow-up studies. “They have to establish data indicating how much protection the vaccine gives. The duration schedule is defined in their protocol. Till that is established, full licensure cannot be granted,” added the official.
